161 filings
Page 6 of 9
DEF 14A
qn8 fqpy72d1
19 Apr 21
Definitive proxy
4:15pm
8-K
natszd0c0yq 88
25 Mar 21
March 2021 Corporate Presentation
8:31am
10-K
sffymy3t
25 Mar 21
Annual report
8:23am
8-K
x2r3t 2f0c
25 Mar 21
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
8:07am
8-K
n7wxitu3a9c76z
5 Mar 21
Other Events
8:03am
8-K
vkc9anwrua9hil 46x8
2 Mar 21
Keros Therapeutics to Present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference
8:06am
8-K
0zzdto
17 Feb 21
Keros Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
8:06am
S-8
nuw9cnypu9a0p p3gwv4
15 Jan 21
Registration of securities for employees
4:28pm
8-K
5i5qmihphgekl4t
21 Dec 20
Keros Therapeutics Announces Addition to NASDAQ Biotechnology Index
8:04am
8-K
yyf 8x4qhep
17 Dec 20
Keros Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors
8:03am
8-K
2cd8qvm nby97
7 Dec 20
Other Events
8:11am
8-K
y8i2uw
17 Nov 20
Keros Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:03pm
8-K
txocikd
13 Nov 20
Keros Therapeutics Announces Pricing of Public Offering of Common Stock
4:07pm
424B4
wu4qtqit7ztlh9ed
13 Nov 20
Prospectus supplement with pricing info
4:02pm
EFFECT
vesr xefsh02rmjl
13 Nov 20
Notice of effectiveness
12:15am
POS EX
fp20dra2ug
13 Nov 20
Additional exhibits for listing
12:00am
S-1MEF
mql7q0tq2o8ne7i25m
12 Nov 20
Registration of additional securities for an S-1
8:35pm
8-K
gi6gp6g5
10 Nov 20
Other Events
5:14pm